Skip to Content
Merck
  • Excitotoxicity and metabolic changes in association with infarct progression.

Excitotoxicity and metabolic changes in association with infarct progression.

Stroke (2014-03-20)
Johannes Woitzik, Alexandra Pinczolits, Nils Hecht, Nora Sandow, Michael Scheel, Christoph Drenckhahn, Jens P Dreier, Peter Vajkoczy
ABSTRACT

We investigated to what extent excitotoxicity and metabolic changes in the peri-infarct region of patients with malignant hemispheric stroke are associated with delayed infarct progression. In 18 patients with malignant hemispheric stroke, 2 microdialysis probes were implanted within the peri-infarct tissue at a distance of 5 and 15 mm to the infarct. Precise probe placement was achieved by intraoperative laser speckle imaging. Glutamate, glucose, pyruvate, and lactate levels were monitored for 5 days after surgery. Delayed infarct progression was determined from serial MRI on the day after surgery and after the monitoring period. Initial stroke volume ranged from 122 to 479 cm3 with a median of 295 cm3. Nine of 18 patients (50%) had delayed infarct progression (median, 44 cm3; range, 19-93 cm3). In these patients, glucose and individual pyruvate levels were significantly lower when compared with patients without infarct progression, whereas glutamate and the lactate-pyruvate ratio were significantly elevated in patients with infarct progression early after surgery (12-36 hours) at the 15-mm microdialysis probe location. Lactate was elevated but without difference between groups. Excitotoxic or metabolic impairment was associated with delayed infarct progression and could serve as a treatment target.

MATERIALS
Product Number
Brand
Product Description

Supelco
Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Lactic acid, natural, ≥85%
Sigma-Aldrich
Lactic acid, 85%, FCC
Sigma-Aldrich
L-Glutamic acid hydrochloride
Sigma-Aldrich
Lactic acid, meets USP testing specifications
Glutamic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Glycerol solution, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Supelco
L-Glutamic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
L-Glutamic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Glutamic acid, FCC
Sigma-Aldrich
Pyruvic acid, natural, ≥95%, FG
Sigma-Aldrich
Pyruvic acid, ≥97%, FG
Sigma-Aldrich
Glycerol, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Glycerol, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
Glycerol, FCC, FG
Sigma-Aldrich
Pyruvic acid, 95%
Sigma-Aldrich
DL-Lactic acid, 85 % (w/w), syrup
Sigma-Aldrich
Glycerin, meets USP testing specifications
Sigma-Aldrich
Glycerol, ≥99.5%
Sigma-Aldrich
L-Glutamic acid, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-100.5%
Sigma-Aldrich
L-Glutamic acid, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
D-Glutamic acid, ≥99% (TLC)
Sigma-Aldrich
Glycerol, BioXtra, ≥99% (GC)
Sigma-Aldrich
L-Glutamic acid, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Glycerol, for molecular biology, ≥99.0%
Sigma-Aldrich
DL-Lactic acid, ~90% (T)
Sigma-Aldrich
Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycerol, ReagentPlus®, ≥99.0% (GC)